---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-009849"
form_type: "8-K"
ticker: "IVF"
cik: "0001417926"
company_name: "INVO Fertility, Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:07:07.176120+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# INVO Bioscience prelim Q4 revenue $270-280K, up 15-19% QoQ; signs Wisconsin clinic acquisition

## Summary
- Q4 2022 revenue expected $270K-$280K, up 15-19% from Q3 2022's $235K.
- Full year 2022 revenue expected $815K-$825K, up 38-40% YoY excluding $3.6M deferred revenue from Ferring.
- Gross operating expenses for FY2022 expected $10.5M-$11.0M, up 14-19% YoY.
- Signed binding purchase agreement for Wisconsin Fertility Institute (clinic generated ~$5.5M revenue, $1.9M net income in trailing 12 months).
- Closed registered direct offering for ~$3M gross proceeds in March 2023; 10-K filing extended to April 15, 2023.

## SEC filing metadata
- accession: 0001493152-23-009849
- form_type: 8-K
- ticker: IVF
- cik: 0001417926
- company_name: INVO Fertility, Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417926/000149315223009849/0001493152-23-009849-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417926/000149315223009849/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-009849
- JSON: https://secwatch.observer/filing/0001493152-23-009849.json
- Plain text: https://secwatch.observer/filing/0001493152-23-009849.txt

## Key facts
- Earnings Releases
  INVO Fertility, Inc. reported preliminary financial results for fourth quarter and year ended December 31, 2022.
  - Period: fourth quarter and year ended December 31, 2022
  - Result: preliminary results
  source text: On March 30, 2023, INVO Bioscience, Inc. (the "Company") issued a press release announcing preliminary financial results for the fourth quarter and the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1417926/000149315223009849/0001493152-23-009849-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.